Marchex operates as a conversation-intelligence and AI-enabled marketing-analytics provider, assisting enterprises in sectors like automotive, home services, and healthcare to convert phone calls, texts, and conversations into usable data. The company's outlook centers on a clear repositioning: shifting from standalone analytics sales to bundled AI-powered offerings that deliver not only insights but also automated actions and confirmed outcomes, such as booked appointments and qualified sales conversations.
This bundling approach sits at the core of the strategy. With its largest customers already depending on Marchex for conversational data, management sees room to lift revenue per customer by adding outcome-based products. Certain bundles could roughly double revenue per customer, expanding the addressable market without needing many new clients. That said, competition is intense from larger marketing-technology platforms with greater scale and resources. A concentrated customer base and smaller research-and-development budget represent structural challenges in keeping pace with better-funded AI rivals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The most significant near-term catalyst is the Archenia acquisition, announced in May 2026 and slated to close in July 2026 pending approval by disinterested stockholders. Archenia focuses on real-time consumer-intent detection and AI-verified, outcome-based customer acquisition. Management expects the combination to create a vertically focused platform covering insights, actions, and outcomes. On a combined basis, guidance points to a revenue run rate of approximately $15 million per quarter, or $60 million annualized, with 15% to 20% growth in 2026 and adjusted EBITDA margins moving toward 10% or higher.
Earnings updates continue to influence sentiment. For the third quarter of 2026, the company expects sequential revenue growth and possible acceleration, with standalone adjusted EBITDA of about $2 million or more, or roughly $2.5 million or more if the Archenia deal closes, implying an annualized run rate of $10 million or more. Management has also highlighted a “Rule of 30 to 40” target, blending annual revenue growth with adjusted EBITDA margins as a medium-term benchmark. From what I see, any new analyst coverage or target change could carry extra weight given the thin coverage. Northland Securities maintains a Buy rating and $4.00 price target on MCHX, with consensus at Moderate Buy and the same average target. A $3 million share-buyback authorization further reflects management’s view that the stock may not fully capture the company’s value.
Marchex’s path ties closely to wider adoption of generative AI and conversational analytics in enterprise marketing. As companies demand clearer returns on customer-acquisition spending, interest in AI-verified outcomes over raw impressions or clicks could support the repositioning. Adoption trends in verticals such as automotive and home services, where phone conversations still drive high-intent purchases, remain especially relevant.
Macro conditions present a mixed picture. The customer base includes discretionary, advertising-heavy sectors that may trim spending if interest rates stay high or consumer demand weakens. Inflation and cost pressures could constrain budgets, while higher financing costs might weigh on small-cap, currently unprofitable firms that investors reward mainly for margin progress. Regulatory developments around AI, data privacy, and call-recording consent also warrant attention, given the reliance on compliant data collection.
Looking ahead, the long-term narrative rests on a few structural elements. If the Archenia integration succeeds, cross-selling and bundling across a larger installed base could unlock what management sees as a $100 million revenue opportunity over time. Cost-structure changes, including platform migration and operational efficiencies, are expected to support margins even before a full revenue pickup.
Margin sustainability will be a key test. Guidance calls for adjusted EBITDA margins of 10% or more in 2026, though maintaining that level depends on operating-expense discipline and turning early paid pilots into recurring, higher-value subscriptions. Technology transitions carry execution risk: shifting customers to the newer Marchex Engage platform has already produced some revenue dilution, and further friction could delay the growth inflection. Competitive pressure from larger AI and marketing-technology vendors, along with revenue concentration in a small number of customers, remains the biggest structural concern. Capital-allocation moves, including the buyback and the Archenia transaction, will indicate how aggressively management aims to strengthen its position. Consensus estimates point to a return to profitability in a few years, and with a single covering analyst at a $4.00 target, sentiment should stay sensitive to execution milestones.
One tool I’ve found useful for monitoring possible directional moves in names like this is Tickeron’s AI Trend Prediction Engine. It supplies AI-powered forecasts to help identify whether a stock may trend bullish, bearish, or sideways over the next week or month, along with historical context and alert features. Pairing these signals with the fundamental catalysts discussed here can provide a more complete forward view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for MCHX moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 22 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MCHX as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for MCHX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 44 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
MCHX moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MCHX crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCHX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MCHX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +8.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCHX advanced for three days, in 161 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MCHX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.016) is normal, around the industry mean (-1.659). P/E Ratio (-10.154) is within average values for comparable stocks, (21.041). Projected Growth (PEG Ratio) (0.780) is also within normal values, averaging (1.501). MCHX's Dividend Yield (1.515) is considerably higher than the industry average of (0.084). P/S Ratio (1.439) is also within normal values, averaging (1.815).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. MCHX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCHX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of advertising and marketing services
Industry AdvertisingMarketingServices